Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Inclusion Criteria: * Diagnosis of PRP by clinical assessment and biopsy. * Male subject age 18-99. * Female subject age 18-99; either of non-childbearing potential or of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks following the last dose of ixekizumab. * PASI score of 10 or greater at baseline. * Are a candidate for phototherapy and/or systemic therapy. * Willingness to travel to OHSU for all study visits, OR living \>30 miles from OHSU and willing/able to participate in remote videoconferencing visits with access to a computer with internet capabilities and webcam. * Have given written informed consent approved by the OHSU Investigational Review Board. Exclusion Criteria: * Known malignancy or lymphoproliferative disease (except treated basal cell skin cancer, treated squamous cell skin cancer, or treated cervical carcinoma in situ) for at least 5 years. * Active, untreated, acute or chronic infection (such as untreated tuberculosis), or immunocompromised to an extent that such that participation in the study would pose an unacceptable risk to the subject. (Treated infections such as latent tuberculosis after completion of the appropriate therapy are not excluded.) * Positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus. * Previous treatment with any agent that targets interleukins 17 specifically. * Systemic treatment…